Table 2 Objective response, surgical and pathological profile of patients
Characteristics | |
|---|---|
Objective response per RECIST v1.1, n (%, 95% CI) (N = 48) | |
Complete response | 3 (6.2%, 1.3–17.2%) |
Partial response | 30 (62.5%, 47.4–76.0%) |
Stable disease | 15 (31.2%, 18.7–46.3%) |
Objective response rate | 33 (68.8%, 53.7–81.3%) |
Disease control rate | 48 (100.0%, 92.6–100.0%) |
Surgical and pathological profile (N = 45) | |
Interval between last neoadjuvant and surgery (day), mean (standard deviation) | 33.7 (4.0) |
Surgical perdure, n (%) | |
Ivor-Lewis | 28 (62.2%) |
McKeown | 17 (37.8%) |
Cumulative operative time (min), median (range) | 240 (170–405) |
Blood loss (mL), median (range) | 50 (20–1500) |
Conversion, n (%) | 0 |
R0 resection, n (%) | 100 (100.0%) |
Number of resected lymph nodes, median (range) | 33 (13–52) |
Major complications, n (%) | |
Anastomotic leakage | 2 (4.4%) |
Chylothorax | 1 (2.2%) |
Atrial fibrillation | 5 (11.1%) |
Vocal-cord paralysis | 2 (4.4%) |
Pneumonia | 11 (24.4%) |
Reoperation | 1 (2.2%) |
90-day mortally | 0 |
Unexpected admission to intensive care unit, n (%) | 1 (2.2%) |
Pathological response, n (%, 95% CI) | |
PCR | 14 (31.1%, 18.2–46.6%) |
Non-PCR | 31 (68.9%, 53.4–81.8%) |
Adjuvant therapy, n (%) | |
No | 5 (11.1%) |
Serplulimab and chemotherapy | 17 (37.8%) |
Serplulimab and radiotherapy | 2 (4.4%) |
Serplulimab | 21 (46.7%) |
